2020
Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention
Abraham NS, Yang EH, Noseworthy PA, Inselman J, Yao X, Herrin J, Sangaralingham LR, Ngufor C, Shah ND. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention. Alimentary Pharmacology & Therapeutics 2020, 52: 646-654. PMID: 32657466, PMCID: PMC8183594, DOI: 10.1111/apt.15790.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedClopidogrelCohort StudiesFemaleGastrointestinal HemorrhageHumansMaleMiddle AgedPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPostoperative ComplicationsPrasugrel HydrochlorideRetrospective StudiesThromboembolismTicagrelorTreatment OutcomeUnited StatesConceptsPercutaneous coronary interventionAcute coronary syndromeGIB ratesGIB riskCoronary syndromeGastrointestinal bleedingSTEMI patientsCoronary interventionHazard ratioMajor adverse cardiac eventsRisk reductionCox proportional hazards modelNSTE-ACS patientsAdverse cardiac eventsMajor bleeding eventsConfidence intervalsInverse probability treatmentProportional hazards modelMedicare Advantage enrolleesBleeding eventsClopidogrel prescriptionGIB eventsNSTE-ACSGastrointestinal bleedBaseline characteristics
2016
Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications
Gershman B, Van Houten HK, Herrin J, Moreira DM, Kim SP, Shah ND, Karnes RJ. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications. European Urology 2016, 71: 55-65. PMID: 26995328, DOI: 10.1016/j.eururo.2016.03.015.Peer-Reviewed Original ResearchConceptsRate of biopsyProstate-specific antigen (PSA) screeningPredictors of complicationsPostbiopsy complicationsUSPSTF recommendationsAntigen screeningProstate biopsyRelative morbidityScreening TrialUS Preventive Services Task Force (USPSTF) recommendationOvarian Cancer Screening TrialAmerican Urological Association guidelinesMorbidity of biopsyPrior fluoroquinolone useEuropean Randomized StudyCancer Screening TrialInterrupted time series analysisProportion of menTask Force recommendationsInfectious complicationsAnticoagulant useComplication rateUnderwent biopsyRandomized studyScreening guidelines